07:00 – 18:00
North Tower
- Junior Ballroom Foyer
Conference Registration
07:00 – 18:00
North Tower
- Junior Ballroom Foyer
Internet Café
07:00 – 18:00
North Tower (lower lobby)
- Gulf Island A
Speaker Ready Room
07:00 – 18:00
B Tower
- Beluga
Sponsor Lounge – BD
07:00 – 18:00
B Tower
- Blue Whale
Sponsor Lounge – Diasorin
07:00 – 18:00
South Tower (4th floor)
- Columbia
Sponsor Lounge – bioMérieux
07:00 – 18:00
North Tower
- Parksville
Escape Room
07:00 - 17:00
Sign Up (last group entrance 17:00)
07:00 – 08:30
North Tower (4th floor)
- Port McNeill
CACMID AGM
07:00 – 08:30
North Tower (4th floor)
- Port Alberni
AMMI Canada Communications Committee Meeting
07:00 - 07:30
Breakfast
07:30 - 08:30
Meeting
08:30 – 10:00
North Tower
- Grand Ballroom BC
Plenary
Challenges and Advances to Implementing Diagnostics and Care in Rural and Remote Settings in Canada
MODERATORS:
Vanessa Tran (ON)
Ninad Mehta (SK)
SPEAKERS:
David Goldfarb (BC)
Kim Dionne (NU)
John Kim (MB)
At the end of this session, participants should be able to:
- Review the impact on quality of care and health outcomes for populations with limited access to laboratory medicine
- Describe specific challenges encountered in the development of laboratory medicine in rural and remote settings
- Identify strategies and learn about success stories in improving access to laboratory medicine in Canada
10:00 – 17:30
North Tower
- Pavilion Ballroom and Junior Ballroom
Exhibit Hall Open / Poster Viewing
10:00 – 10:30
North Tower
- Pavilion Ballroom and Junior Ballroom
Break
10:30 – 11:30
North Tower
- Grand Ballroom BC
Respiratory Syncytial Virus (RSV) Burden of Disease in Infants – A Need for All Infant Protection
(co-developed learning activity)
MODERATOR:
Prameet Sheth (ON)
SPEAKER:
Cora Constantinescu (AB)
At the end of this session, participants should be able to:
- Describe the seasonality of RSV and understand the burden of disease related to RSV in all infants
- Summarize RSV prevention strategies through monoclonal antibodies and maternal vaccines
- Recognize opportunities for success and potential challenges with the implementation of public RSV prophylaxis programs across Canada
This educational event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada. The program was co-developed with AMMI Canada and Sanofi and was planned to achieve scientific integrity, objectivity, and balance.
Under the guidance of the Innovative Medicines Canada Code of Ethical Practices this event is for healthcare professionals only.
11:30 – 13:00
North Tower
- Pavilion Ballroom and Junior Ballroom
Lunch in Exhibit Hall
11:45 – 12:45
North Tower
- Pavilion Ballroom and Junior Ballroom
Your Title Goes Here
Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
Poster Presenters at Posters to Answer Questions
| TP001 (#4) | Culture-independent detection of Helicobacter pylori antimicrobial resistance markers in stool by metagenomic sequencing Presenting: Kaye Quizon |
| TP002 (#17) | Validation of Copan Amies gel swabs for the detection of Streptococcus pyogenes in throats on GeneXpert Xpress Group A Strep assay Presenting: Melissa Caza |
| TP003 (#44) | Determining the limit of detection of antibiotic broth-enrichment, culture based, and PCR-based methods for the detection of vancomycin-resistant enterococci and carbapenemase-producing Enterobacterales Presenting: Jay Wieler |
| TP004 (#52) | Evaluation of TB Xpert® MTB/Rif Ultra assay on formalin-fixed paraffin embedded tissues for Mycobacterium tuberculosis diagnosis Presenting: Shazia Masud |
| TP005 (#59) | Validation of a two commercial serology assays for the detection of antibodies against mpox virus Presenting: Ana Citlali Marquez |
| TP006 (#62) | Development of an Amplicon-based whole genome sequencing assay for Respiratory Syncytial Virus Presenting: Henry Wong |
| TP007 (#63) | Evaluation of the QIAstat-Dx® Respiratory SARS-CoV-2 Panel for the detection of viral and bacterial pathogens in nasopharyngeal swab specimens Presenting: Melissa Caza |
| TP008 (#67) | Detection of bacteria directly from synovial fluid using digital PCR: A proof of concept study Presenting: Corrie Belanger |
| TP009 (#80) | Change in the Streptococcus pyogenes (group A streptococcus, GAS) positivity rates among throat swabs submitted from community settings in British Columbia Presenting: Eugene Yeung |
| TP010 (#81) | To beat or not to beat–An exploratory assessment of two commercial fecal DNA extraction methods with and without bead-beating for quantitative polymerase chain reaction-based detection of gastrointestinal protozoa Presenting: LingHui Su |
| TP011 (#92) | Cerebrospinal fluid galactomannan detection for the diagnosis of central nervous system aspergillosis: a diagnostic test accuracy systematic review and meta-analysis Presenting: Adam Komorowski |
| TP012 (#105) | Low-level (< 1 x 106 cfu/L) Streptococcus agalactiae bacteriuria in pregnancy is significantly associated with antepartum colonization Presenting: Ariel Ang |
| TP013 (#107) | Evaluation of the NG-Test® CTX-M MULTI lateral flow immunoassay Presenting: Geneviève Amaral |
| TP014 (#108) | Investigating the performance of typhoid diagnostics and molecular analysis of Salmonella entericavirulence Presenting: Emmanuel Kweku Sam |
| TP015 (#115) | Evaluation of the Seegene STARlet-AIOSTM compared to the conventional STARlet system using the AllplexTM Entero-DR Assay Presenting: Jay Wieler |
| TP016 (#117) | Monitoring of Legionella pneumophila out breaks through Next Generation Sequencing-based genotyping: Comparison assessment with PFGE and SBT Presenting: Cindy Lalancette |
| TP017 (#118) | Candida auris identification using CHROMagar™ Candida Plus and qPCR Presenting: Xiao Rui (Lisa) Li |
| TP018 (#124) | Performance evaluation of complete urine culture categorization by WASPLab PhenoMATRIX Presenting: Leah Brown |
| TP019 (#130) | Xpert MTB/RIF Ultra performance on bronchoscopy specimens for tuberculosis (TB) diagnosis in a low-incidence setting Presenting: Cole Schonhofer |
| TP020 (#144) | TaqMan PACMAN: A simple molecular approach for positive rapid antigen test confirmation during periods of low prevalence Presenting: Jason LeBlanc |
| TP021 (#144) | Incidence rates and serotype distribution of human enteroviruses in patients with central nervous system (CNSI) infections in South-central Ontario Presenting: Matthew Surette |
| TP022 (#165) | Comparison of fosfomycin (FOS) MICs generated by reference agar dilution (AD) testing and Etest® for pathogens submitted to a Canadian fosfomycin susceptibility testing service Presenting: Heather Adam |
| TP023 (#167) | Performance of a novel chromogenic agar for primary isolation of pathogenic beta-hemolytic streptococci from throat swabs Presenting: Abdulrahman Almodahka |
| TP024 (#170) | Evaluation of the Seegene STARlet-AIOS™ automation system for respiratory virus testing Presenting: Lauren Zoppa |
| TP025 (#177) | Evaluation and comparison of five commercial stool antigen assays for the diagnosis of Helicobacter pylori Presenting: Lisa Cormier |
| TP026 (#179) | Comparison of genetic resolution in clinical Mycobacterium tuberculosis complex isolates by genotyping and whole genome sequencing methods Presenting: Angela Ma |
| TP027 (#180) | Bruker™ MALDI-ToF MS Compass Library Revision K accurately discriminates Streptococcus pyogenes from Streptococcus dysgalactiae/canis Presenting: Nicholas Kontzie |
| TP028 (#192) | Evaluation of the Xpert® MTB/RIF Ultra for the detection of Mycobacterium tuberculosis in cerebrospinal fluids Presenting: Kerstin Locher |
| TP029 (#199) | Increased seroprevalence of Lyme disease in Nova Scotia: A ten-year update Presenting: Glenn Patriquin |
| TP030 (#201) | Optimizing Leishmania diagnostics: an integrated molecular approach for accurate detection and species identification Presenting: Alan O’Dwyer |
| TP031 (#203) | Workflow comparison and evaluation of an automated instrument for handling sample preparation in clinical laboratory Presenting: Michael Chan |
| TP032 (#206) | Comparing routine C. difficile testing methods to identify C. difficile colonization in asymptomatic patients prior to hematopoietic cell transplantation Presenting: Austin Yan |
| TP033 (#225) | Enhancing influenza surveillance through whole genome sequencing: Implications for local, national, and global pathogen control Presenting: Kara Loos |
| TP034 (#227) | Comparative performance of the BioFire® FilmArray® respiratory panel 2.1 and the GeneXpert® Xpert® SARS-CoV-2/Flu/RSV assays for the detection of respiratory viruses in children using nasopharyngeal swabs Presenting: Abdulrahman Almodahka |
| TP035 (#229) | Detection of atypical bacteria, including Mycoplasma pneumoniae, 2013-2023 Presenting: Tess MacIntyre |
| TP036 (#230) | Multicenter experience on the diagnostic yield of multiplex bacterial PCR for sterile site infections Presenting: Mohammad Hasan |
| TP037 (#233) | Public Health Agency of Canada’s measles and mumps molecular proficiency panel program: a retrospective study examining past results from Canadian laboratories Presenting: Vanessa Zubach |
| TP038 (#240) | Development and Validation of a Low-Cost Semi-Automated High-Throughput Direct Qualitative Loop Mediated Amplification Assay for the Detection of Streptococcus pyogenes from Throat Swab Specimens Presenting: Michael Groesche |
| TP039 (#242) | Development of a Real-Time PCR assay for the detection of Aspergillus species from bronchial specimens Presenting: Billie Velapatino |
| TP040 (#253) | Carbapenemase-producing Enterobacterales in Alberta from 2013–2023 Presenting: Ashley Williams |
| TP041 (#256) | Status of detection of Pneumocystis jiroveci in Canadian clinical microbiology laboratories by the National Molecular Group (NMG) survey Presenting: Greg German |
| TP042 (#262) | Evaluation of a commercial lateral flow immunochromatographic assay, the Alere SA PBP2a test, for detection of Penicillin binding protein 2a (PBP2a) in coagulase negative staphylococcus species Presenting: Esraa Al-Fraihat |
| TP043 | WITHDRAWN |
| TP044 (#268) | Validation of the VITEK®2 AST-N391 susceptibility testing card compared to disc diffusion following 2022 CLSI M100 Presenting: Yerin Lee |
| TP045 (#269) | Trends in antimicrobial resistance among Gram-negative organisms in Toronto, Canada between January 2013 and December 2022 – A notable rise in MDRO and XDRO Klebsiella pneumoniae Presenting: Yerin Lee |
| TP046 (#274) | Investigating clinical microbiology performance in an external quality assessment (EQA) program: A 5-year cross-sectional analysis Presenting: Jennifer Wu |
| TP047 (#282) | Hemophilus influenzae screening and isolation in asymptomatic Cystic Fibrosis patients: Is it worth it? A narrative review Presenting: Arunima Dalai |
| TP048 (#283) | Mycobacterium tuberculosis pseudo-outbreak due to laboratory cross contamination – An epidemiological investigation and phylogenetic analysis Presenting: Nayla Léveillé |
| TP049 (#300) | Transmission of Mycobacterium tuberculosis, a problem inside Colombian prisons Presenting: Mariana Herrera Diaz |
| TP050 (#301) | Evaluation of a provincial Hepatitis C Virus nucleic acid testing reflex program Presenting: Agatha Jassem |
| TP051 (#307) | WITHDRAWN |
| TP052 (#311) | Evaluation of Digital PCR technology for the detection of Mycobacterium tuberculosis DNA in formalin-fixed paraffin-embedded tissues Presenting: Billie Velapatino |
| TP053 (#314) | Replacing the CLSI disk potentiation assay with a semi-automated, cost effective molecular assay for the identification of ESBL producing Escherichia coli, Klebsiellae spp and Proteus mirabilis from surveillance specimens Presenting: Candy Rutherford |
| TP054 (#325) | Evaluation of the utility of secondary confirmatory testing for Neisseria gonorrhoeae identification from culture Presenting: Ellen Avery |
| TP055 (#327) | Road to efficient HIV diagnostic testing: An evaluation of first-time HIV antibody-positive patients receiving follow-up testing in Alberta, Canada, from 2018 to 2023 Presenting: N. Joelle Kasongo |
| TP056 (#336) | An Enhanced National SARS-CoV-2 Surveillance Program: Bringing together genetic and functional characterization of circulating strains to monitor viral antigenicity and the effectiveness of current antiviral therapeutics Presenting: Charlene Ranadheera |
| TP057 (#338) | A pilot study to use a viability real-time PCR assay as a diagnostic tool for patients experiencing Salmonellosis Presenting: Surangi Thilakarathna |
| TP058 (#342) | Testing for extragenital Neisseria gonorrhoeae and Chlamydia trachomatis : at home pharyngeal and rectal self-swabs are non-inferior to those completed in healthcare settings Presenting: Vanessa Tran |
| TP059 (#334) | A challenging O166:H15 STEC strain isolation from patients’ stools Presenting: Surangi Thilakarathna |
| TP060 (#345) | Post-pandemic recrudescence of invasive streptococcal infection: the new epidemiology of pneumococcal bacteremia Presenting: Geneviève Amaral |
| TP061 (#354) | Diagnosis of Helicobacter pylori Infection in British Columbia – Serology vs. Urea Breath Test Presenting: Miguel Imperial |
| TP062 (#357) | Discordance in rifampin resistance determination between a commercial molecular test, whole genome sequencing, and phenotypic testing, for a provincially circulating Mycobacterium tuberculosis strain Presenting: Adrian Kense |
| TP063 (#364) | Impact on turnaround time for Herpes simplex virus (HSV-1/2) testing following implementation of the BioFire FilmArray® Meningitis/Encephalitis Panel in a paediatric hospital Presenting: Emma Finlayson-Trick |
| TP064 (#365) | Theoretical assessment of BioFire Blood Culture Identification Panel 2 for positive blood culture identification in a tertiary care paediatric/obstetric hospital Presenting: Inna Sekirov |
| TP065 (#368) | Development of high-throughput extraction methodology for Legionella pneumophila to support outbreak response in Canada Presenting: Jennifer Tanner |
| TP066 (#83) | Factors associated with paediatric COVID-19 mortality: A Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) Study Presenting: Michael Prodanuk |
| TP067 (#123) | Evaluation of self/parent collected oral nasal swabs for respiratory illness in symptomatic children Presenting: Hannah Nelson |
| TP068 (#157) | Cytomegalovirus transmission in mismatched paediatric solid organ transplant recipients – What factors are at play? Presenting: Geraldine Huynh |
| TP069 (#249) | Increasing frequency of intracranial complications of sinusitis in children: A single centre retrospective study before and after emergence of SARS-CoV-2 Presenting: Charis Huddle |
| TP070 (#138) | Exploring updates to contact tracing recommendations for potential measles exposure on an airplane Presenting: Katie Graham |
| TP071 (#189) | A rise in the frequency of carbapenemase-producing Enterobacterales following an initial decline post COVID-19 Presenting: Ceylon Simon |
| TP072 (#202) | Idexx Legiolert for the detection of Legionella pneumophila: benefits and limitations as a potential alternative to agar culture for public health testing of environmental waters Presenting: Hyojin Jeong |
| TP073 (#237) | Evaluation of test positivity rate for rotavirus in one province from 2013 to 2023 Presenting: Caroline Quach-Thanh |
| TP074 (#250) | The effect of antimicrobial copper on pathogenic and environmental microorganisms in high-traffic non-clinical settings Presenting: Kelsey Cruz |
| TP075 (#284) | Could blood establishments help in evaluating whether HTLV-1/2 screening should be conducted in high-risk pregnant women? Presenting:Christian Renaud |
| TP076 (#294) | Assessing the public health impact of the adjuvanted respiratory syncytial virus prefusion F (RSVPreF3) vaccine in Canadian older adults Presenting: Sydney George |
| TP077 (#303) | Improving vaccine uptake: Immunization governance in Atlantic Canada Presenting: Rachel Parker |
| TP078 (#319) | Dried blood spot sampling for HIV, hepatitis C, and syphilis testing: Evaluating provincial implementation of an innovative testing modality Presenting: Janice Duddy |
| TP079 (#323) | The Community Pop-up Clinic (CPC): Cascade of Care and HCV Treatment in vulnerable population of people who use drugs (PWUD) Presenting: Shana Yi |
| TP080 (#346) | Impact of new sexual behaviour-based screening practice at Héma Québec Presenting: Christian Renaud |
| TP081 (#347) | Respiratory Syncytial Virus: the use of the Moving Epidemic Method to guide the launch of palivizumab immunoprophylaxis campaigns in Québec Presenting: Christian Renaud |
| TP082 (#355) | Molecular Screening Reveals Low Prevalence of Ixodes scapularis ticks in British Columbia: Implications for Tick Identification Methods Presenting: Isaac Singh |
| TP083 (#56) | Motivation to opt-out of quality improvement project for universal third trimester screening of chlamydia and gonorrhea at a single hospital site in Alberta Presenting: Taylor Walsh |
| TP084 (#121) | Characterization of Mycoplasma genitalium in Canada from 2022 to 2023 Presenting: Nick Nordal-Budinsky |
| TP085 (#147) | Mycoplasma genitalium infection in a cohort of adolescents and young women Presenting: Angela Copete |
| TP086 (#193) | Ceftriaxone resistant Neisseria gonorrhoeae strains in Canada, 2017-2023 Presenting: Robyn Thorington |
| TP087 (#223) | Evaluating the Performance of Dried Blood Spot Samples for Sexually Transmitted Blood Borne Infection Testing Presenting: Jennifer Kopetzky |
| TP088 (#322) | Multiple Syphilis Infections episodes in British Columbia: Molecular Analysis using Enhanced CDC-rpsA Typing and Point Mutation Detection Presenting: Pink Yi Lui |
| TP089 (#326) | Genomic characterization of circulating Treponema pallidum strains in British Columbia, 2023 Presenting: Min-Kuang Lee |
| TP090 (#348) | Investigation of the newly emerging 14d/d Treponema pallidum strain in British Columbia using multilocus sequence typing Presenting: Julia Wang |
| TP091 (#125) | Evaluation of the updated cobas® SARS-CoV-2 & Influenza A/B Qualitative nucleic acid test (v2) for the detection of influenza A H1N1 containing matrix mutation C124A Presenting: Christopher Lowe |
| TP092 (#159) | Targeting Hepatitis B Virus by pretending to be Hepatitis Delta Virus Presenting: Justine Beghin |
| TP093 (#211) | Detecting proliferation of rubella-specific memory T-cells in the prenatal population Presenting: Tamara Semeria Maitret |
| TP094 (#217) | Clinical Significance of Human Herpesvirus 6 detected with the Film Array Meningitis/Encephalitis Panel in Nova Scotia Presenting: Yahya Shabi |
| TP095 (#286) | Characterization of live attenuated and UV-inactivated VSV-based influenza universal vaccine targeting the highly conserved M2 ectodomain from different host strains Presenting: Titus Olukitibi |
| TP096 (#334) | Identification of nsp5 mutations in SARS-CoV-2 isolates from patients after completion of nirmatrelvir-ritonavir therapy through whole-genome sequencing Presenting: Natalie Deschenes |
| TP097 (#248) | Epidemiology of paediatric invasive pneumococcal disease (IPD) late after introduction of a routine infant PCV13 program Presenting: Altynay Shigayeva |
13:00 – 14:30
North Tower
- Grand Ballroom A
Masterclass C
Oral Antibiotic Therapies for Infections in Paediatrics and Adults - Implications for Infectious Disease and Medical Microbiology
(pre-registration required to maximum of 150 participants)
MODERATOR:
William Connors (BC)
SPEAKERS:
Jennifer Grant (BC)
Amesh Adalja (PA, USA)
At the end of this session, participants should be able to:
- Understand the evidence for use of oral antibiotics for serious bacterial infections (ie: bacteremia, endovascular infection, deep seated/bone and joint infections)
- Appreciate the laboratory and clinical challenges of implementing oral antibiotic regimens into routine clinical care
- Review key areas of uncertainty and barriers to more wide-spread use of oral antibiotics for serious bacterial infection and among patients marginalized in the healthcare system (i.e.: persons who inject drugs, experiencing homelessness)
13:00 – 14:30
North Tower
- Grand Ballroom D
Masterclass D
Infectious Issues with Immunotherapy (Monoclonal antibodies, targeted therapies, bispecifics, and cellular therapies)
(pre-registration required to maximum of 150 participants)
MODERATOR:
Peter Pieroni (MB)
SPEAKERS:
David Szwajcer (MB)
Versha Banerji (MB)
At the end of this session, participants should be able to:
- Describe the prevalence of infectious disease complications of immunotherapy
- Summarize a standardized approach to working up patients from an infectious disease perspective starting immunotherapy or suffering from an infectious complication
14:45 – 15:45
North Tower
- Grand Ballroom BC
State of the Art (START) Lecture
Microbiology and Infections in Transgender and Gender-Diverse Patients
MODERATORS:
Philippe Lagacé-Wiens (MB)
Marthe Charles (BC)
SPEAKERS:
Jessica Prodger (ON)
Emery Potter (ON)
Ben Peto (ON)
At the end of this session, participants should be able to:
- Review gender affirming care, genital health and factors that may have an impact on the microbiota and infections
- Describe the appropriate handling and result interpretation of microbiological specimens from gender-diverse patients
- Understand the patient experience of gender-diverse people in accessing infectious diseases care
16:00 – 17:00
North Tower
- Grand Ballroom A
Increasing Cervical Cancer Prevention Worldwide
(co-developed learning activity, pre-registration required to maximum of 150 participants)
MODERATOR:
Prameet Sheth (ON)
SPEAKERS:
Philippe Descamps (FR)
Lananh Nguyen (ON)
At the end of this session, participants should be able to:
- Summarize why cervical cancer is the fastest growing cancer in Canadian females
- Describe the WHO recommendations towards elimination of cervical cancer
- Summarize the international and local responses to the WHO recommendations including the ACCESS International Consensus Group on Cervical Cancer
This educational event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada. The program was co-developed with AMMI Canada and Hologic and was planned to achieve scientific integrity, objectivity, and balance.
Under the guidance of the Innovative Medicines Canada Code of Ethical Practices this event is for healthcare professionals only.
16:00 – 17:00
North Tower
- Grand Ballroom D
Adapting to the Times: Vaccination’s Crucial Role in RSV, Flu, COVID-19, and Pneumococcal Disease
(co-developed learning activity, pre-registration required to maximum of 150 participants)
MODERATOR:
Cora Constantinescu (AB)
SPEAKERS:
Allison McGeer (ON)
Angel Chu (AB)
At the end of this session, participants should be able to:
- Review the epidemiology of RSV, influenza, COVID-19, and pneumococcal disease
- Discuss strategies and best practices to help reduce the burden of these common infections
- Explore how new vaccinations fit into current prevention paradigms
This educational event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada. The program was co-developed with AMMI Canada and Pfizer Canada and was planned to achieve scientific integrity, objectivity, and balance.
Under the guidance of the Innovative Medicines Canada Code of Ethical Practices this event is for healthcare professionals only.
17:00 – 17:15
North Tower
- Grand Ballroom Foyer
Break
17:15 – 18:15
North Tower
- Grand Ballroom A
Your Title Goes Here
Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
Oral Presentations Session B
Moderator: William Connors (BC)
| 17:15 – 17:30 B01 (#61) |
Candida auris in Canada, 2012 – Oct 2023 Presenting: Amrita Bharat |
| 17:30 – 17:45 B02 (#358) |
Congenital Syphilis in Canada: Clinical and health-care related diagnosis and treatment findings of a Canadian Paediatric Surveillance Program Study (June 2021-May 2023) Presenting: Jared Bullard |
| 17:45 – 18:00 B03 (#100) |
Mailed antibiotic prescribing feedback to primary care physicians: A factorial randomized controlled trial Presenting: Kevin Schwartz |
| 18:00 – 18:15 B04 (#178) |
Macrolide and Fluoroquinolone Resistant Mycoplasma genitalium in Canada, 2018-2023 Presenting: Shelley Peterson |
17:15 – 18:15
North Tower
- Grand Ballroom D
Your Title Goes Here
Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
Rapid Fire Student Presentations Sessions B
Moderator: Danielle Brabant-Kirwan (ON)
| 17:15 – 17:20 RFB01 (#69) |
Use of Dalbavancin in treatment of Acute Bacterial Skin and Skin Structure Infections: Prospective Case Series from a Canadian Perspective Presenting: Wayne Leung |
| 17:20 – 17:25 RFB02 (#258) |
Verification of the Aptima Bacterial Vaginosis (BV) and Candida/Trichomonas (CV/TV) assays on the Hologic Panther Presenting: Emily MacAdam |
| 17:25 – 17:30 RFB03 (#41) |
Clinical validation of an optimized and automated agnostic diagnostic assay for detection of respiratory viruses Presenting: Nick Gauthier |
| 17:30 – 17:35 RFB04 (#58) |
Multivariate analysis of risk factors predicting 28 -day mortality among adult patients presenting with bacteremia in the emergency department Presenting: Noémie Laurier |
| 17:35 – 17:40 RFB05 (#75) |
Infectious diseases consultation is associated with reduced mortality in hospitalized patients with Gram-negative bloodstream infection: a population-wide cohort study Presenting: Sean Ong |
| 17:40 – 17:45 RFB06 (#198) |
HCV Reinfection Among People Who Use Drugs (PWUD) Treated For HCV Infection: A Long -Term View Presenting: Saina Beitari |
| 17:45 – 17:50 RFB07 (#213) |
Impact of antimicrobial copper surfaces on microbial load and healthcare-acquired infection rates in long -term care settings: a comparative study in Canada Presenting: Hasan Hamze |
| 17:50 – 17:55 RFB08 (#133) |
MRSA isolates resistant to trimethoprim-sulfamethoxazole by VITEK2 and BD Phoenix antibiotic susceptibility testing systems but susceptible by Etest and disk diffusion harbour a resistant subpopulation Presenting: Farhan Khan |
| 17:55 – 18:00 RFB09 (#270) |
Validation of Python scripts vs. Excel for cleaning, analysis, and visualization of surveillance and methods evaluation data Presenting: Yerin Lee |
| 18:00 – 18:05 RFB10 (#287) |
Impacts of SARS -CoV -2 and non-pharmaceutical interventions on the seasonal incidence of hospitalizations for acute respiratory diseases among children Presenting: Christina Lukac |
| 18:05 – 18:10 RFB11 (#306) |
Clinical and public health management of bacterial gastroenteritis in the world of culture -independent diagnostic testing (CIDT): A pilot study to evaluate kinetics of bacterial shedding by culture and CIDT Presenting: Nathan McCartney |
| 18:10 – 18:15 RFB12 (#324) |
SARS -CoV -2 seropositivity in Alberta: the Omicron era Presenting: Sa’adiya Umar |